New Antiresorptive Therapies for Postmenopausal Osteoporosis

키워드

참고문헌 (61)

1. "FDA approves new injectable osteoporosis treatment for postmenopausal women" (2010)[URL]
2. "Prolia (denosumab)" (2015)[URL]
3. "Prolia® (denosumab)" (2010)[URL]
4. Cummings SR., "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)
5. Kong YY., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", Nature, 397, pp.315~323 (1999)
6. Bekker PJ., "A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women", J Bone Miner Res, 19, pp.1059~1066 (2004)
7. Lobo ED., "Antibody pharmacokinetics and pharmacodynamics", J Pharm Sci, 93, pp.2645~2668 (2004)
8. Boonen S., "Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk", J Clin Endocrinol Metab, 96, pp.1727~1736 (2011)
9. Papapoulos S., "Five years of denosumab exposure in women with postmenopausal osteoporosis : results from the first two years of the FREEDOM extension", J Bone Miner Res, 27, pp.694~701 (2012)
10. McClung MR., "Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis", J Bone Miner Res, 27, pp.211~218 (2012)
11. Brown JP., "Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass : a randomized, blinded, phase 3 trial", J Bone Miner Res, 24, pp.153~161 (2009)
12. Kendler DL., "Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy", J Bone Miner Res, 25, pp.72~81 (2010)
13. Block GA., "A singledose study of denosumab in patients with various degrees of renal impairment", J Bone Miner Res, 27, pp.1471~1479 (2012)
14. Bone HG., "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", J Clin Endocrinol Metab, 96, pp.972~980 (2011)
15. Brown JP., "Bone remodeling in postmenopausal women who discontinued denosumab treatment : off-treatment biopsy study", J Bone Miner Res, 26, pp.2737~2744 (2011)
16. Kendler DL., "Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate", Osteoporos Int, 22, pp.1725~1735 (2011)
17. Watts NB., "Infections in postmenopausal women with osteoporosis treated with denosumab or placebo : coincidence or causal association?", Osteoporos Int, 23, pp.327~337 (2012)
18. Martín-Baez IM., "Severe hypocalcaemia post-denosumab", Nefrologia, 33, pp.614~615 (2013)
19. McLachlan JM., "Severe symptomatic hypocalcaemia following a single dose of denosumab", Med J Aust, 199, pp.242~243 (2013)
20. Ungprasert P., "Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency", Am J Emerg Med, 31, pp.756 e1~756 e2 (2013)
21. Stopeck AT., "Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study", J Clin Oncol, 28, pp.5132~5139 (2010)
22. "Denosumab 60 mg (prolia▼)" (2013)[URL]
23. Bucay N., "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", Genes Dev, 12, pp.1260~1268 (1998)
24. Helas S., "Inhibition of receptor activator of NFkappaB ligand by denosumab attenuates vascular calcium deposition in mice", Am J Pathol, 175, pp.473~478 (2009)
25. Janda K., "Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis", Pol Arch Med Wewn, 123, pp.149~155 (2013)
26. Augoulea A., "Osteoprotegerin as a marker of atherosclerosis in diabetic patients", Int J Endocrinol, 2013, pp.182060~ (2013)
27. Mogelvang R., "Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP", Heart, 99, pp.106~110 (2013)
28. Kiechl S., "Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease", Circulation, 109, pp.2175~2180 (2004)
29. Reid IR., "Effects of denosumab on bone histomorphometry : the FREEDOM and STAND studies", J Bone Miner Res, 25, pp.2256~2265 (2010)
30. Silva I., "Denosumab : recent update in postmenopausal osteoporosis", Acta Reumatol Port, 37, pp.302~313 (2012)
31. Chlebowski RT., "Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women", JAMA, 304, pp.1684~1692 (2010)
32. Anderson GL., "Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy : extended follow-up of the Women's Health Initiative randomised placebo-controlled trial", Lancet Oncol, 13, pp.476~486 (2012)
33. Komm BS., "Bazedoxifene acetate : a selective estrogen receptor modulator with improved selectivity", Endocrinology, 146, pp.3999~4008 (2005)
34. Crabtree JS., "Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland", Mol Cell Endocrinol, 287, pp.40~46 (2008)
35. Peano BJ., "Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland", Endocrinology, 150, pp.1897~1903 (2009)
36. Van Duren D., "Bazedoxifene combined with conjugated estrogens : A novel alternative to traditional hormone therapies", Fertil Steril, 86, pp.S88~S89 (2006)
37. Harvey JA., "Breast density changes in a randomized controlled trial evaluating bazedoxifene", conjugated estrogens, 2013, pp.20, 138~145
38. Pinkerton JV., "Breast effects of bazedoxifene-conjugated estrogens : a randomized controlled trial", Obstet Gynecol, 121, pp.959~968 (2013)
39. Lindsay R., "Efficacy of tissue-selective estrogen complex of bazedoxifene", conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women, 2009, pp.92, 1045~1052
40. Pinkerton JV., "Effects of bazedoxifene", conjugated estrogens on the endometrium and bone: a randomized trial, 2014, E189~E198
41. Lobo RA., "Evaluation of bazedoxifene", conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile, 2009, pp.92, 1025~1038
42. Pinkerton JV., "Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene", conjugated estrogens : a randomized, controlled trial, 2009, pp.16, 1116~1124
43. Kagan R., "A randomized, placebo-and active-controlled trial of bazedoxifene", conjugated estrogens for treatment of moderate to severe vulvar, Menopause, pp.2010, 17[DOI]
44. Bachmann G., "Effects of bazedoxifene", conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar, Climacteric, pp.2010, 13[DOI]
45. Skouby SO, "Low risk of thrombophilia with bazedoxifene", conjugated estrogens: summary of pooled coagulation data from the selective estrogens, menopause, and response to therapy trials, 2012, ~
46. Archer DF., "Bazedoxifene", conjugated estrogens(BZA, Fertil Steril, pp.2009, 92[DOI]
47. "DUAVEE® (conjugated estrogens/bazedoxifene) tablets for oral use" (2013)[URL]
48. Ng KW., "Potential role of odanacatib in the treatment of osteoporosis", Clin Interv Aging, 7, pp.235~247 (2012)
49. Vääräniemi J., "Intracellular machinery for matrix degradation in bone-resorbing osteoclasts", J Bone Miner Res, 19, pp.1432~1440 (2004)
50. Xia L., "Localization of rat cathepsin K in osteoclasts and resorption pits : inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones", Biol Chem, 380, pp.679~687 (1999)
51. Furuyama N., "Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts", Steroids, 65, pp.371~378 (2000)
52. Troen BR., "The regulation of cathepsin K gene expression", Ann N Y Acad Sci, 1068, pp.165~172 (2006)
53. Black WC., "The consequences of lysosomotropism on the design of selective cathepsin K inhibitors", Chembiochem, 7, pp.1525~1535 (2006)
54. Kim TS., "Non-covalent cathepsin K inhibitors for the treatment of osteoporosis", Curr Top Med Chem, 6, pp.355~360 (2006)
55. Gauthier JY., "The discovery of odanacatib(MK-0822), a selective inhibitor of cathepsin K", Bioorg Med Chem Lett, 18, pp.923~928 (2008)
56. Bone HG., "Odanacatib, a cathepsin-K inhibitor for osteoporosis : a two-year study in postmenopausal women with low bone density", J Bone Miner Res, 25, pp.937~947 (2010)
57. Langdahl B., "Odanacatib in the treatment of postmenopausal women with low bone mineral density : five years of continued therapy in a phase 2 study", J Bone Miner Res, 27, pp.2251~2258 (2012)
58. "Merck announces data from pivotal phase 3 fracture outcomes study for odanacatib, an investigational oral, once-weekly treatment for osteoporosis" (2014)[URL]
59. Khosla S., "Odanacatib : location and timing are everything", J Bone Miner Res, 27, pp.506~508 (2012)
60. Masarachia PJ., "Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys", J Bone Miner Res, 27, pp.509~523 (2012)
61. Balena R., "Bone resorption and formation on the periosteal envelope of the ilium : a histomorphometric study in healthy women", J Bone Miner Res, 7, pp.1475~1482 (1992)

관련 논문AI추천